Canakinumab (ACZ885, a fully human IgG1 anti-IL-1beta mAb) induces sustained remission in pediatric patients with cryopyrin-associated periodic syndrome (CAPS) - Kuemmerle-Deschner, J B; Ramos, E; Blank, N (Arthritis research & therapy, 2011)
et al.